No Data
Xiamen Amoytop Biotech (688278.SH): awarded 4.798 million restricted stocks to 673 incentive recipients.
Gelonghui September 26th | xiamen amoytop biotech (688278.SH) announced that the company has set September 25, 2024 as the first date of granting, granting 4.798 million restricted stocks to 673 incentive objects at a grant price of 39.80 yuan per share.
Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug
Do Xiamen Amoytop Biotech's (SHSE:688278) Earnings Warrant Your Attention?
Sinolink Securities: The large pharmaceutical sector is a key point in the mid-year report, and it is expected to see a overall recovery in the pharmaceutical sector in the second half of the year.
Looking ahead to the second half of the year, with the decline in the base, the recovery of procurement sentiment, and the stabilization of policy expectations, I am bullish on the recovery of demand for pharmaceutical and medical device products within hospitals, as well as the acceleration of performance growth. The pharmaceutical sector is expected to experience an overall reversal in the second half of the year.
Xiamen Amoytop Biotech Fiscal 2024 Profit Jumps 51%, Operating Income Up 32%; Shares Surge 14%
Xiamen Amoytop Biotech: Half-year report for the year 2024.
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention TodayNo Data
No Data
